All Stories

AstraZeneca's Alexion accused of extending Soliris monopoly through sham patents in new suit

Nonprofit health plan EmblemHealth claims that AstraZeneca's Alexion unit fraudulently won extra patents on rare disease blockbuster Soliris, extending its monopoly for four years.

Apr 17, 2025 - 17:06
 0
AstraZeneca's Alexion accused of extending Soliris monopoly through sham patents in new suit
Nonprofit health plan EmblemHealth claims that AstraZeneca's Alexion unit fraudulently won extra patents on rare disease blockbuster Soliris, extending its monopoly for four years.
Read More

Tags:

Previous Article

Volkswagen Will Hold Firm On Imported Vehicle Prices - For Now

Next Article

Lectric eBikes’ Earth Day Sale 2025: Your Next Adventure Starts Now

Related Posts

Canada locks down an initial 500K doses of GSK's bird flu vaccine

Canada locks down an initial 500K doses of GSK's bird f...

Feb 20, 2025  0

Meet the Tech That’s Modernizing How HCPs Get Meds to Patients

Meet the Tech That’s Modernizing How HCPs Get Meds to P...

Apr 4, 2025  0

Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors

Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FD...

Apr 3, 2025  0